|
- Immunization, Vaccines and Biologicals - World Health . . .
Trivalent oral polio vaccine (tOPV) – protects against poliovirus types 1, 2, and 3 - following the "OPV Switch" in April 2016, tOPV is no longer in use Bivalent oral polio vaccine (bOPV) – protects against poliovirus types 1, and 3
- History of polio vaccination - World Health Organization (WHO)
The ease of administering the oral vaccine made it the ideal candidate for mass vaccination campaigns Hungary began to use it in December 1959 and Czechoslovakia in early 1960, becoming the first country in the world to eliminate polio
- Two Polio Vaccines - World Health Organization (WHO)
Poliomyelitis (polio) is a highly infectious viral disease that largely affects children under 5 years of age The virus is transmitted by person-to-person spread mainly through the faecal-oral route or, less frequently, by a common vehicle (e g contaminated water or food) and multiplies in the intestine, from where it can invade the nervous system and cause paralysis
- Poliomyelitis - World Health Organization (WHO)
Polio vaccine, given multiple times, can protect a child for life There are two vaccines available: oral polio vaccine and inactivated polio vaccine Both are effective and safe, and both are used in different combinations worldwide, depending on local epidemiological and programmatic circumstances, to ensure the best possible protection to populations can be provided
- Poliomyelitis - World Health Organization (WHO)
Inactivated Polio Vaccine (IPV) The requirements for poliomyelitis vaccine (inactivated) were first formulated in 1959 and revised in 1965 Following several advances in technology in vaccine production, the requirements were further
- Immunization, Vaccines and Biologicals - World Health . . .
The Immunization, Vaccines and Biologicals department is responsible for targeting vaccine-preventable diseases, guiding immunization research and establishing immunization policy WHO Indonesia A child receiving oral polio drops
- Safety profile of nOPV2 vaccine - World Health Organization . . .
The novel oral polio vaccine (nOPV2) is currently in the wider use roll-out phase under WHO Emergency Use Listing (EUL) for the control of type 2 circulating vaccine-derived poliovirus (cVDPV2) outbreaks, in line with the Strategic Advisory Group of Experts on Immu nization (SAGE) guidance
- Circulating vaccine-derived poliovirus type 2 (cVDPV2 . . .
On 9 May 2025, the International Health Regulations (IHR) National Focal Point (NFP) for Papua New Guinea (PNG) notified WHO of the detection of circulating vaccine-derived poliovirus type 2 (cVDPV2) from stool specimens of two healthy children from Morobe province, Papua New Guinea (PNG) The detection of wild poliovirus (WPV) or vaccine-derived poliovirus (VDPV), including from samples taken
|
|
|